구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk) Daiichi Sankyo / AstraZeneca·TROP2 50 trials·t½ ADC ~6 days; released DXd cleared rapidly |
|---|---|
Overview Program | Datroway (datopotamab deruxtecan) |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | TROP2 |
Overview Indication | HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. |
Positioning Known limitation | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. |
Positioning Development positioning | Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target. |
Technology Payload | DXd (exatecan derivative, topoisomerase I inhibitor) |
Technology Linker | Tetrapeptide-based cleavable maleimide linker, DAR ~4 |
Technology DAR | DAR 4 |
MoA Mechanism | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. |
MoA Biomarker | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. |
PK/PD Half-life | ADC ~6 days; released DXd cleared rapidly |
PK/PD Species | Cynomolgus monkey, Mouse, PFS by BICR, ctDNA and TROP2 QCS exploratory |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse, Rat, Hamster |
Toxicology Major finding | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Toxicology CRS | N/A |
Clinical Safety signal | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Clinical Selected reported efficacy | ORR 79% |
Clinical Reported ORR | 74% |
Clinical Reported PFS | 4.4 |
Clinical Reported OS | 12.9 |
Clinical Result source | ClinicalTrials.gov NCT04656652 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04656652 |
Preclinical Animal (cat.) | Mouse, In vitro |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk) Daiichi Sankyo / AstraZeneca·TROP2 50 trials·t½ ADC ~6 days; released DXd cleared rapidly |
|---|---|
Overview Program | Datroway (datopotamab deruxtecan) |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | TROP2 |
Overview Indication | HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. |
Positioning Known limitation | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. |
Positioning Development positioning | Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target. |
Technology Payload | DXd (exatecan derivative, topoisomerase I inhibitor) |
Technology Linker | Tetrapeptide-based cleavable maleimide linker, DAR ~4 |
Technology DAR | DAR 4 |
MoA Mechanism | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. |
MoA Biomarker | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. |
PK/PD Half-life | ADC ~6 days; released DXd cleared rapidly |
PK/PD Species | Cynomolgus monkey, Mouse, PFS by BICR, ctDNA and TROP2 QCS exploratory |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse, Rat, Hamster |
Toxicology Major finding | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Toxicology CRS | N/A |
Clinical Safety signal | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. |
Clinical Selected reported efficacy | ORR 79% |
Clinical Reported ORR | 74% |
Clinical Reported PFS | 4.4 |
Clinical Reported OS | 12.9 |
Clinical Result source | ClinicalTrials.gov NCT04656652 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04656652 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교